Core Insights - Revenue grew 105% year-over-year to $2.2 million, driven by expanded adoption of the first-generation LungFit PH system across more than 45 hospitals [1] - Customer retention exceeds 90% with over half of the current customer base secured under multiyear agreements, providing a stable foundation for future Gen II conversion [1] - The commercial strategy has shifted toward high-priority hospitals that are likely to adopt Gen I immediately and expand usage once the transport-compatible Gen II system is approved [1] Financial Performance - Operating expenses were reduced by 36% year-over-year, reflecting disciplined cost-cutting in SG&A and the completion of major R&D spending for the Gen II regulatory filing [1] Strategic Moves - The divestiture of the NeuroNOS subsidiary to XTL Biopharmaceuticals allows the company to focus resources on core commercial operations while retaining a 19.9% equity stake and up to $31.5 million in milestones [1] - International expansion reached 40 countries, with management noting a transition from initial device placement to recurring revenue from accessory reorders [1]

Core Insights - Beyond Air, Inc. has been awarded a national group purchasing agreement for therapeutic gases with Premier, Inc., effective July 15, 2025, allowing Premier members to access special pricing for the LungFit PH system and disposable NO2 Smart Filters [1][2] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on utilizing nitric oxide (NO) to enhance patient care, particularly for respiratory illnesses and neurological disorders [8][10] - The LungFit PH system is designed to deliver nitric oxide on demand from ambient air, providing a cylinder-free solution that improves safety and operational efficiency in healthcare settings [2][5] Product Details - The LungFit PH system can deliver NO doses ranging from 0.5 ppm to 80 ppm, with a standard delivery of 20 ppm for ventilated patients, and each Smart Filter provides 12 hours of therapy [2][5] - The system operates using only the power equivalent to a 60-watt lightbulb, minimizing nitrogen dioxide (NO2) byproduct levels [2][5] - Beyond Air's LungFit PH is approved for commercial use in multiple regions, including the U.S., EU, and Australia, while other LungFit systems are still in investigational stages [7][8] Strategic Partnerships - The agreement with Premier was facilitated by HealthCare Links, a consulting group specializing in national group purchasing organization access [4] - Premier serves a significant portion of U.S. healthcare providers, enhancing the distribution and accessibility of Beyond Air's products [3] Market Potential - The LungFit system has the potential to replace traditional high-pressure NO cylinders, significantly reducing inventory and storage needs in hospitals [5][6] - Beyond Air is also exploring the use of its technology for treating severe lung infections and chronic conditions in both hospital and home settings [6][9]